



Program

Monday, June 9

08:30-09:00 Opening remarks: Ralph Lindemann and Olaf Witt
Welcome: Prof. Christof von Kalle, Director National Center for Tumor Diseases Heidelberg

09:00 – 10:30 Mechanism(s) of action I (Chair: Ralph Lindemann)

Wynne Aherne (London, UK) HDAC Inhibitors and the molecular chaperone HSP90 – a therapeutic mechanism of action

Manfred Jung (Freiburg, GER) Synthesis and Biological Activity of Histone deacetylase inhibitors that target tubulin

Saverio Minucci (Milan, IT) Chromatin alterations in leukemogenesis

10:30 – 10:45 Coffee Break

10:45 – 12:15 Mechanism(s) of action II (Chair: Ricky Johnstone)

Lucia Altucci (Naples, IT) HDAC Inhibitors: mechanism(s) of action in leukemia models targeting multiple epigenetic enzymes

Hedwig Deubzer (Heidelberg, GER) Activation of BMP4 signaling via inhibition of HDAC11

Thorsten Heinzel (Jena, GER) Mechanisms of HDAC inhibitor action – targets beyond chromatin

Program contd.

12:20 – 13:20 Lunch

13:20 – 14:50 Mechanism(s) of action III (Chair: Olaf Witt)

Rainer Glauben Histone deacetylase as targets in models of inflammation-related tumorigenesis
(Berlin, GER)

Ralph Lindemann In vivo candidate screen for apoptotic genes mediating therapeutic activity of
(Heidelberg, GER) Vorinostat

Martin Göttlicher HDAC2 in colorectal cancer
(Munich, GER)

14:50 – 15:05 Coffee break

15:05 – 16:35 Clinical efficacy I (Chair: Robert Brown)

Ulrich Mahlknecht Role of Valproic acid in the treatment of AML and MDS
(Homburg/Saar, GER)

Pamela Munster HDAC inhibitor induced modulation of anti-estrogen therapy
(Tampa, Florida, US)

Kevin Kelly The early clinical development of Vorinostat (SAHA)
(Yale, Connecticut, US)

Refreshing Break

17:30 Invited speakers: Bus transfer for Tour of the Heidelberg Castle and Old Town

20:00 Invited speakers: Informal Dinner in the Old Town Restaurant “Kulturbrauerei” and further discussions

Tuesday, June 10

09:00 – 10:30 Clinical efficacy II (Chair: Jean-Pierre Issa)

Janine Arts JNJ-26481585: a novel “second-generation” oral pan-Histone Deacetylase
(Beerse, BEL) inhibitor

Rudolf Stadler First experiences with Vorinostat in cutaneous T-cell lymphoma
(Minden, GER)

Nicholas LaThangue Clinical application of HDAC inhibitors: defining biomarkers that predict tumour
(Oxford, UK) responses

10:30 – 10:45 Coffee Break



Program contd.

10:45-12:15 Rational drug combinations (Chair: Pamela Munster)

Ricky Johnstone (Melbourne, Australia) Enhancing the apoptotic and therapeutic anti-cancer effects of histone deacetylase inhibitors

Robert Brown (London, UK) Combination approaches to overcoming acquired drug resistance in ovarian cancer

Jean-Pierre Issa (Houston, Texas, US) Combinations of DNA methylation inhibitors with histone deacetylase inhibitors in leukemias

12:15 Closing remarks

12:30-13:30 Lunch and farewell

This workshop is kindly supported by

Supported by:



German José Carreras Leukemia-Foundation

